Breakthrough Biodegradable Capsule Aids Hemophilia Treatment
|
By Daniel Beris Posted on 13 Dec 2016 |
|
Image: A hemophilia capsule only degrades in the small intestine (Photo courtesy of UT Austin).
A new study describes how an innovative biodegradable capsule that uses hydrophilic carriers for oral delivery of hematological factor IX (hFIX) can treat hemophilia B.
Developed by researchers at the University of Texas (UT; Austin, USA), the oral delivery system is based on a pH-responsive polymer hydrogel microcarrier system that carries the prophylactic hFIX particles. The poly (methacrylic acid)-grafted-poly(ethylene glycol) [P(MAA-g-EG)] polymer, synthesized using ultraviolet (UV) polymerization, is subsequently joined with an enzymatically degradable peptide crosslinking agent that allows for site-specific degradation (by trypsin) in the small intestine.
As it moves through the body, the particle-containing capsule resists the major gastric enzyme in order to remain intact while in the stomach, protecting the encapsulated drug. When in the small intestine, the capsule begins to swell with the increase in pH, and is subsequently degraded by the minor intestinal enzyme, slowly releasing the drug over time. In study models, the system successfully transported hFIX, and was able to deliver adequate levels of the drug to the target site in the small intestine. The study was published on November 15, 2016, in the International Journal of Pharmaceutics.
“While an oral delivery platform will be beneficial to all hemophilia B patients, patients in developing countries will benefit the most,” said lead author Sarena Horava, PhD, of the UT Cockrell School of Engineering. “In many developing countries, the median life expectancy for hemophilia patients is 11 years due to the lack of access to treatment, but our new oral delivery of factor IX can now overcome these issues and improve the worldwide use of this therapy.”
Hemophilia B is a blood clotting disorder caused by a mutation of the factor IX gene, leading to a deficiency of factor IX. It is the second-most common form of hemophilia, and is sometimes called Christmas disease, after Stephen Christmas, the first patient described with the affliction. Presentation of hemophilia B is consistent with easy bruising, urinary tract bleed, and nosebleeds. Current protein replacement therapies rely on intravenous (IV) injections and infusions.
Related Links:
University of Texas
Developed by researchers at the University of Texas (UT; Austin, USA), the oral delivery system is based on a pH-responsive polymer hydrogel microcarrier system that carries the prophylactic hFIX particles. The poly (methacrylic acid)-grafted-poly(ethylene glycol) [P(MAA-g-EG)] polymer, synthesized using ultraviolet (UV) polymerization, is subsequently joined with an enzymatically degradable peptide crosslinking agent that allows for site-specific degradation (by trypsin) in the small intestine.
As it moves through the body, the particle-containing capsule resists the major gastric enzyme in order to remain intact while in the stomach, protecting the encapsulated drug. When in the small intestine, the capsule begins to swell with the increase in pH, and is subsequently degraded by the minor intestinal enzyme, slowly releasing the drug over time. In study models, the system successfully transported hFIX, and was able to deliver adequate levels of the drug to the target site in the small intestine. The study was published on November 15, 2016, in the International Journal of Pharmaceutics.
“While an oral delivery platform will be beneficial to all hemophilia B patients, patients in developing countries will benefit the most,” said lead author Sarena Horava, PhD, of the UT Cockrell School of Engineering. “In many developing countries, the median life expectancy for hemophilia patients is 11 years due to the lack of access to treatment, but our new oral delivery of factor IX can now overcome these issues and improve the worldwide use of this therapy.”
Hemophilia B is a blood clotting disorder caused by a mutation of the factor IX gene, leading to a deficiency of factor IX. It is the second-most common form of hemophilia, and is sometimes called Christmas disease, after Stephen Christmas, the first patient described with the affliction. Presentation of hemophilia B is consistent with easy bruising, urinary tract bleed, and nosebleeds. Current protein replacement therapies rely on intravenous (IV) injections and infusions.
Related Links:
University of Texas
Gold Member
12-Channel ECG
CM1200B
Hybrid Arch Device
Neo EDE
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Latest Critical Care News
- Multi-Night Home Monitoring Reduces Sleep Apnea Misdiagnosis
- AI-Guided Outreach System Improves Colorectal Cancer Screening
- FDA Breakthrough Device Targets Brain Hemorrhage Complications
- RFA Device Gains FDA Clearance for Minimally Invasive Thyroid Nodule Ablation
- ECG-Based Screening Framework Aims to Standardize Cardiac Evaluation in Military Personnel
- Inhaled Analgesic Matches Morphine for Prehospital Trauma Pain
- FDA Clears Tongue-Applied Neuromodulation System for Stroke Gait Rehabilitation
- Eye Test May Predict Return of Consciousness After Severe Brain Injury
- Medical Drone Program Improves Blood Access and Patient Survival
- AI System Enables Real-Time Sepsis Quality Assessment and Improves Adherence
- AI Detects Hidden ECG Marker of Sudden Cardiac Death
- FDA-Cleared AI Wearable Monitor Detects Opioid-Related Respiratory Risk in Hospitals
- Mitral Valve Repair Device Receives EU Approval for Functional Regurgitation
- AI Risk Score Reveals Hidden Hypertension-Related Organ Damage
- AI Tool Predicts Bronchopulmonary Dysplasia Risk in Preterm Infants
- Optical Brain Monitoring Predicts Neurodevelopmental Outcomes in Preterm Infants
Channels
Artificial Intelligence
view channel
AI Tool Predicts Chronic Kidney Disease Risk in Diabetes
Chronic kidney disease is a common and serious complication of type 2 diabetes and often progresses without obvious early symptoms, increasing morbidity and straining health systems. Many risk models were... Read more
AI Trends Report Guides Responsible, Effective Healthcare Deployment
Hospitals are under growing pressure to adopt artificial intelligence tools that improve safety, efficiency, and continuity of care without compromising quality. At the same time, clinicians need clearer... Read more
Surgical Techniques
view channel
Novel Microparticles Break Down Biofilms and Boost Antibiotic Activity
Biofilms are dense matrices of bacteria and proteins that shield microbes from disinfectants and drugs. They complicate wound care and the reprocessing of surgical instruments because standard agents often... Read more
Nerve Block Technique Reduces Opioid Use After Cardiac Surgery
Opioid exposure after open-heart surgery is associated with delirium, nausea, and other complications, and may contribute to longer-term dependence. Because cardiac procedures often still require high... Read more
Patient Care
view channel
AI Avatar Doctor Improves Patient Understanding Before Radiotherapy
Radiation oncology consultations require patients to grasp complex concepts quickly, yet anxiety and information overload often undermine understanding and informed consent. Poor comprehension can also... Read more
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Health IT
view channel
Digital Heart Model Supports Targeted Ablation in Atrial Fibrillation
Atrial fibrillation is an erratic, quivering heartbeat and a leading cause of stroke. Catheter ablation is widely used to interrupt arrhythmogenic tissue, yet many patients—especially with persistent ... Read more
AI Framework Helps Clinicians Create Trustworthy Risk Prediction Tools
Artificial intelligence (AI) is increasingly used to estimate risks for conditions such as sepsis, heart disease, and cancer, yet many models remain difficult for clinicians to interpret or trust.... Read more
Point of Care
view channel
New Brain Ultrasound Platform Enables Bedside Postoperative Imaging
Transporting postoperative patients for CT or MRI can create operational burdens, delays, and disruptions in care. Bedside visualization may help reduce transport demands, lower radiation exposure, and... Read more
Handheld Ultrasound Expands Point-of-Care Imaging Access in Brazil
Rapid access to diagnostic imaging is essential across hospitals, emergency departments, clinics, and municipal health systems, but large markets still face uneven availability, particularly in rural regions.... Read more
Business
view channel
Danaher Completes Acquisition of Masimo to Expand Patient Monitoring Capabilities
Danaher Corporation (Washington, DC, USA) has completed its acquisition of Masimo Corporation (Irvine, CA, USA), a specialty diagnostics provider known for pulse oximetry and advanced patient monitoring... Read more
